NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines
The paper discusses the position of beta-blockers, nebivolol in particular, in the Reappraisal 2009 of ESH/ESC Guidelines on arterial hypertension (AH) management. Nebivolol is not only highly selective towards beta-1 angiotensin II receptors, but also metabolically neutral, and therefore, could be...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2010-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2150 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250712850006016 |
|---|---|
| author | V. I. Makolkin |
| author_facet | V. I. Makolkin |
| author_sort | V. I. Makolkin |
| collection | DOAJ |
| description | The paper discusses the position of beta-blockers, nebivolol in particular, in the Reappraisal 2009 of ESH/ESC Guidelines on arterial hypertension (AH) management. Nebivolol is not only highly selective towards beta-1 angiotensin II receptors, but also metabolically neutral, and therefore, could be used in AH patients with metabolic disorders. |
| format | Article |
| id | doaj-art-c1490d0502a144d789dde89c4321d44d |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2010-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-c1490d0502a144d789dde89c4321d44d2025-08-20T03:57:09Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252010-12-019692961859NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC GuidelinesV. I. Makolkin0I.M. Sechenov First Moscow State Medical UniversityThe paper discusses the position of beta-blockers, nebivolol in particular, in the Reappraisal 2009 of ESH/ESC Guidelines on arterial hypertension (AH) management. Nebivolol is not only highly selective towards beta-1 angiotensin II receptors, but also metabolically neutral, and therefore, could be used in AH patients with metabolic disorders.https://cardiovascular.elpub.ru/jour/article/view/2150arterial hypertensionbeta-blockersnebivololmetabolic disorders |
| spellingShingle | V. I. Makolkin NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines Кардиоваскулярная терапия и профилактика arterial hypertension beta-blockers nebivolol metabolic disorders |
| title | NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines |
| title_full | NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines |
| title_fullStr | NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines |
| title_full_unstemmed | NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines |
| title_short | NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines |
| title_sort | nebivolol and the 2009 esh update to the 2007 esh esc guidelines |
| topic | arterial hypertension beta-blockers nebivolol metabolic disorders |
| url | https://cardiovascular.elpub.ru/jour/article/view/2150 |
| work_keys_str_mv | AT vimakolkin nebivololandthe2009eshupdatetothe2007eshescguidelines |